Aspen Neuroscience
Series CAspen Neuroscience is a clinical-stage, private biotechnology company headquartered in San Diego, CA, developing personalized (autologous) iPSC-derived cell replacement therapies for Parkinson's disease and other CNS disorders. Its lead product, ANPD001 (sasineprocel), is derived from a patient's own skin cells reprogrammed into induced pluripotent stem cells and differentiated into dopaminergic neuronal precursor cells (DANPCs) for surgical transplantation. The therapy has received FDA Fast Track designation and is currently being evaluated in the ASPIRO Phase 1/2a clinical trial.
